About Arialys Therapeutics

Arialys Therapeutics, a private biotech company founded by Avalon BioVentures, Catalys Pacific, and MPM Capital, is exploring scientific breakthroughs in autoimmune neurology to develop new precision medicines for autoimmune neurological and neuropsychiatric diseases. Our lead therapeutic candidate, ART5803, is being developed as a potential treatment for anti-NMDA receptor encephalitis (ANRE), a life-threatening neurological disease that causes severe psychosis. ART5803 also has potential to treat autoimmune dementia. The Arialys team has decades of experience identifying biomedical research innovations with the potential to address significant unmet medical needs and building novel therapeutics to bring to the clinic.


Clinical Advisory Board


Marty Jefson, PhD

CEO, Pinteon Therapeutics

Divyanshu (Div) Dubey, MBBS

Associate Professor of Neurology, and Laboratory Medicine and Pathology at Mayo Clinic

Jeffrey M. Gelfand, MD

Associate Professor, Neurology at UCSF Weill Institute for Neurosciences

Mark P. Gorman, MD

Director Pediatric Neuro-immunology Center, Boston Children's Hospital

Benjamin M. Greenberg, MD, MHS

Vice Chair of Clinical and Translational Research for the Department of Neurology at UTSW

Elizabeth Ann Molloy Wells, MD, MHS

Vice President of the Neuroscience and Behavioral Medicine Center at Children’s National Hospital

Sean J. Pittock, MD

Director of Mayo Clinic's Neuroimmunology Laboratory and Center for MS and Autoimmune Neurology